Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jan-Dec:23:23259582241269837.
doi: 10.1177/23259582241269837.

Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study

Cassidy A Gutner  1 , Marc van der Valk  2 , Joaquin Portilla  3 , Eliette Jeanmaire  4 , Leïla Belkhir  5 , Thomas Lutz  6 , Rebecca DeMoor  7 , Rekha Trehan  8 , Jenny Scherzer  9 , Miguel Pascual-Bernáldez  10 , Mounir Ait-Khaled  8 , Beatriz Hernandez  10 , Annemiek de Ruiter  8 , Savita Bakhshi Anand  11 , Emma L Low  11 , Monica Hadi  11 , Nicola Barnes  11 , Nick Sevdalis  12 , Perry Mohammed  8 , Maggie Czarnogorski  1
Affiliations
Multicenter Study

Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study

Cassidy A Gutner et al. J Int Assoc Provid AIDS Care. 2024 Jan-Dec.

Abstract

Introduction: CARISEL is an implementation-effectiveness "hybrid" study examining the perspectives of people living with HIV-1 (patient study participants [PSPs]) on cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) dosed every 2 months (Q2M) across 5 European countries.

Methods: PSPs completed questionnaires on acceptability (Acceptability of Intervention Measure), appropriateness (Intervention Appropriateness Measure), and feasibility (Feasibility of Intervention Measure) at their first (Month [M] 1), third (M4), and seventh (M12) injection visits. Semistructured qualitative interviews were also conducted.

Results: Overall, 437 PSPs were enrolled, of whom 430 received treatment. Median (interquartile range) age was 44 (37-51) years, 25.3% (n = 109/430) were female (sex at birth), and 21.9% (n = 94/430) were persons of color. Across time points, PSPs found CAB + RPV LA highly acceptable, appropriate, and feasible (mean scores ≥4.47/5). Qualitative data supported these observations.

Conclusions: PSPs found CAB + RPV LA Q2M to be an acceptable, appropriate, and feasible treatment option.

Keywords: acceptability; appropriateness; cabotegravir + rilpivirine; long-acting; satisfaction; stigma.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CAG, RM, RT, JS, MP-B, MA-K, BH, AdR, PM and MC are employees of ViiV Healthcare and may be stockholders of GSK. MvdV has received research grants and fees for participation in advisory boards from ViiV, MSD and Gilead. JP reports grants from Gilead and ViiV Healthcare and payments from lectures from Gilead and Janssen. EJ has received speaking fees or consulting activities from ViiV and Gilead laboratories and hospitality and congress registrations from ViiV, Gilead, MSD and Pfizer laboratories. LB and TL have no conflicts of interest to report. SBA, ELL, MH and NB are employees of Evidera who were paid by GSK/ViiV Healthcare to conduct the CARISEL study. NS is the director of London Safety and Training Solutions Ltd, which offers training and improvement and implementation solutions to healthcare organisations and the pharmaceutical industry.

Figures

Figure 1.
Figure 1.
Acceptability, Appropriateness and Feasibility of CAB + RPV LA over time for PSPs*. *Acceptability, appropriateness, and feasibility measures are rated on a 1 to 5 Likert scale: 1 = “completely disagree”; 2 = “disagree”; 3 = “neither agree nor disagree”; 4 = “agree”; 5 = “completely agree.” †Month 1, n = 376. ‡Month 1, n = 376; Month 4, n = 373; Month 12, n = 376. CAB, cabotegravir; LA, long-acting; PSP, patient study participant; RPV, rilpivirine; SD, standard deviation. “Abstract P123—Figure 1. Acceptability, appropriateness, and feasibility* of CAB + RPV LA over time.” Lutz et al HIV Glasgow, October 23-26, 2022, Glasgow, UK / Virtual –https://onlinelibrary.wiley.com/doi/10.1002/jia2.26009. CC BY 4.0.
Figure 2.
Figure 2.
Direct participant quotations from Interviews at Month 12.
Figure 3.
Figure 3.
Summary of Difficulties Relating to CAB + RPV LA. *Only responses given by >5% of PSPs at either time point are shown. Responses are not mutually exclusive. CAB, cabotegravir; LA, long-acting; PSP, patient study participant; RPV, rilpivirine.
Figure 4.
Figure 4.
PSPs preferred HIV-1 Therapy at Month 12 (A) and Reasons for Preference (B). *Includes data from PSPs who selected only one leading checkbox (ie, “Daily oral HIV medication” or “Long-acting injectable HIV medication”). All erroneous and missing data were excluded. †Includes data from PSPs who selected only one leading checkbox (ie, “Daily oral HIV medication” or “LA injectable HIV medication”). All erroneous and missing data were excluded. Responses are not mutually exclusive. Two participants (0.7%) preferred daily oral medication. Both participants (0.7%) selected the reason: “It is more convenient for me to take my HIV medication every day.” A single participant (0.4%) selected the reasons: “I want to avoid injection pain and side effects from the injection,” “I am afraid of needles and injections,” “It is inconvenient for me to visit the HIV clinic to receive injections,” “I believe daily oral medication is more reliable than injections to keep my viral load undetectable,” and “I feel more in control of managing my HIV condition.” LA, long-acting; PSP, patient study participant; Q2M, every 2 months.
See this image and copyright information in PMC

References

    1. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475-490. doi: 10.2147/PPA.S192735 - DOI - PMC - PubMed
    1. de Los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study. AIDS Behav. 2021;25(3):961-972. doi: 10.1007/s10461-020-03055-1 - DOI - PMC - PubMed
    1. Mantsios A, Murray M, Karver TS, et al. Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials. AIDS Behav. 2020;24(12):3473-3481. doi: 10.1007/s10461-020-02918-x - DOI - PubMed
    1. Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220 - DOI - PMC - PubMed
    1. D'Amico R, Margolis DA. Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection. Curr Opin HIV AIDS. 2020;15(1):13-18. doi: 10.1097/COH.0000000000000606 - DOI - PubMed

Publication types

LinkOut - more resources